Be Aware of SGLT2 Inhibitor Risks

SGLT2 inhibitor (empagliflozin, etc) risks will be back in the spotlight...due to recent label changes.

These meds are getting more use now that most have proven CV benefits...despite usually costing about $500/month.

Be familiar with how to manage SGLT2 inhibitor risks.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals